<DOC>
	<DOC>NCT00842894</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to investigate the incidence of serious adverse drug reactions when using NovoMix速 30 (biphasic insulin aspart 30) or Levemir速 (insulin detemir) for treatment of type 2 diabetes mellitus under normal clinical practice conditions in Macedonia.</brief_summary>
	<brief_title>Safety of NovoMix速 30 or Levemir速 for Treatment of Type 2 Diabetics in Macedonia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>After the physician decision has been made to use biphasic insulin aspart 30 or insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newlydiagnosed subjects who have never received insulin or an insulin analogue before.Particular attention should be paid to the drug interactions that are listed within the product label Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit Subjects currently being treated with biphasic insulin aspart 30 or insulin detemir Subjects who were previously enrolled in this study Subjects with a hypersensitivity to biphasic insulin aspart 30 or insulin detemir or to any of the excipients Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>